FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W747233123> ?p ?o ?g. }

• W747233123 endingPage "153" @default.
• W747233123 startingPage "131" @default.
• W747233123 abstract "Worldwide, coronary heart disease accounts for 7 million deaths each year. In Sweden, acute coronary syndrome (ACS) is a leading cause of hospitalization and is responsible for 1 in 4 deaths. The aim of this analysis was to assess the cost-effectiveness of rivaroxaban 2.5 mg twice daily (BID) in combination with standard antiplatelet therapy (ST-APT) versus ST-APT alone, for the secondary prevention of ACS in adult patients with elevated cardiac biomarkers without a prior history of stroke/transient ischemic attack (TIA), from a Swedish societal perspective, based on clinical data from the global ATLAS ACS 2-TIMI 51 trial, literature-based quality of life data and costs sourced from Swedish national databases. A Markov model was developed to capture rates of single and multiple myocardial infarction (MI), ischemic and hemorrhagic stroke, thrombolysis in myocardial infarction (TIMI) major, minor, and “requiring medical attention” bleeds, revascularization events, and associated costs and utilities in patients who were stabilized after an initial ACS event. Efficacy and safety data for the first 2 years came from the ATLAS ACS 2-TIMI 51 trial. Long-term probabilities were extrapolated using safety and effectiveness of acetylsalicylic acid data, which was estimated from published literature, assuming constant rates in time. Future cost and effects were discounted at 3.0%. Univariate and probabilistic sensitivity analyses were conducted. In the base case, the use of rivaroxaban 2.5 mg BID was associated with improvements in survival and quality-adjusted life years (QALYs), yielding an incremental cost per QALY of 71,246 Swedish Krona (SEK) (€8045). The outcomes were robust to changes in inputs. The probabilistic sensitivity analysis demonstrated rivaroxaban 2.5 mg BID to be cost-effective in >99.9% of cases, assuming a willingness-to-pay threshold of SEK 500,000 (€56,458). Compared with ST-APT alone, the use of rivaroxaban 2.5 mg BID in combination with ST-APT can be considered a cost-effective treatment option for ACS patients with elevated cardiac biomarkers without a prior history of stroke/TIA in Sweden. Bayer Pharma AG." @default.
• W747233123 created "2016-06-24" @default.
• W747233123 creator A5000549535 @default.
• W747233123 creator A5006102954 @default.
• W747233123 creator A5021026018 @default.
• W747233123 creator A5023365434 @default.
• W747233123 creator A5061316225 @default.
• W747233123 creator A5061557141 @default.
• W747233123 creator A5065978967 @default.
• W747233123 creator A5076926659 @default.
• W747233123 date "2015-06-23" @default.
• W747233123 modified "2023-10-07" @default.
• W747233123 title "Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden" @default.
• W747233123 cites W1553345686 @default.
• W747233123 cites W1582447064 @default.
• W747233123 cites W1991446776 @default.
• W747233123 cites W2014783633 @default.
• W747233123 cites W2044279453 @default.
• W747233123 cites W2074634974 @default.
• W747233123 cites W2075733100 @default.
• W747233123 cites W2084168392 @default.
• W747233123 cites W2098332177 @default.
• W747233123 cites W2105397247 @default.
• W747233123 cites W2117254307 @default.
• W747233123 cites W2117677020 @default.
• W747233123 cites W2120972109 @default.
• W747233123 cites W2122317738 @default.
• W747233123 cites W2140501627 @default.
• W747233123 cites W2163874686 @default.
• W747233123 cites W2166950143 @default.
• W747233123 cites W2169387542 @default.
• W747233123 cites W2171530447 @default.
• W747233123 cites W3030817736 @default.
• W747233123 cites W4211060556 @default.
• W747233123 cites W4211213494 @default.
• W747233123 doi "https://doi.org/10.1007/s40119-015-0041-3" @default.
• W747233123 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4675751" @default.
• W747233123 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26099515" @default.
• W747233123 hasPublicationYear "2015" @default.
• W747233123 type Work @default.
• W747233123 sameAs 747233123 @default.
• W747233123 citedByCount "5" @default.
• W747233123 countsByYear W7472331232018 @default.
• W747233123 countsByYear W7472331232019 @default.
• W747233123 countsByYear W7472331232020 @default.
• W747233123 crossrefType "journal-article" @default.
• W747233123 hasAuthorship W747233123A5000549535 @default.
• W747233123 hasAuthorship W747233123A5006102954 @default.
• W747233123 hasAuthorship W747233123A5021026018 @default.
• W747233123 hasAuthorship W747233123A5023365434 @default.
• W747233123 hasAuthorship W747233123A5061316225 @default.
• W747233123 hasAuthorship W747233123A5061557141 @default.
• W747233123 hasAuthorship W747233123A5065978967 @default.
• W747233123 hasAuthorship W747233123A5076926659 @default.
• W747233123 hasBestOaLocation W7472331231 @default.
• W747233123 hasConcept C112930515 @default.
• W747233123 hasConcept C126322002 @default.
• W747233123 hasConcept C127413603 @default.
• W747233123 hasConcept C164705383 @default.
• W747233123 hasConcept C194828623 @default.
• W747233123 hasConcept C2776301958 @default.
• W747233123 hasConcept C2777698277 @default.
• W747233123 hasConcept C2777995511 @default.
• W747233123 hasConcept C2778661090 @default.
• W747233123 hasConcept C2779161974 @default.
• W747233123 hasConcept C2779581417 @default.
• W747233123 hasConcept C2780645631 @default.
• W747233123 hasConcept C3019080777 @default.
• W747233123 hasConcept C500558357 @default.
• W747233123 hasConcept C64332521 @default.
• W747233123 hasConcept C71924100 @default.
• W747233123 hasConcept C78519656 @default.
• W747233123 hasConceptScore W747233123C112930515 @default.
• W747233123 hasConceptScore W747233123C126322002 @default.
• W747233123 hasConceptScore W747233123C127413603 @default.
• W747233123 hasConceptScore W747233123C164705383 @default.
• W747233123 hasConceptScore W747233123C194828623 @default.
• W747233123 hasConceptScore W747233123C2776301958 @default.
• W747233123 hasConceptScore W747233123C2777698277 @default.
• W747233123 hasConceptScore W747233123C2777995511 @default.
• W747233123 hasConceptScore W747233123C2778661090 @default.
• W747233123 hasConceptScore W747233123C2779161974 @default.
• W747233123 hasConceptScore W747233123C2779581417 @default.
• W747233123 hasConceptScore W747233123C2780645631 @default.
• W747233123 hasConceptScore W747233123C3019080777 @default.
• W747233123 hasConceptScore W747233123C500558357 @default.
• W747233123 hasConceptScore W747233123C64332521 @default.
• W747233123 hasConceptScore W747233123C71924100 @default.
• W747233123 hasConceptScore W747233123C78519656 @default.
• W747233123 hasIssue "2" @default.
• W747233123 hasLocation W7472331231 @default.
• W747233123 hasLocation W7472331232 @default.
• W747233123 hasLocation W7472331233 @default.
• W747233123 hasLocation W7472331234 @default.
• W747233123 hasLocation W7472331235 @default.
• W747233123 hasLocation W7472331236 @default.
• W747233123 hasOpenAccess W747233123 @default.
• W747233123 hasPrimaryLocation W7472331231 @default.

• next